Axitinib, also known as AG013736, is an orally bioavailable tyrosine kinase inhibitor. Axitinib inhibits the proangiogenic cytokines vascular endothelial growth factor (VEGF) and platelet-derived growth factor receptor (PDGF), thereby exerting an anti-angiogenic effect. A xitinib has received FDA (27 January 2012), EMA (13 September 2012), MHRA (3 September 2012) and TGA (26 July 2012) approval for use as a treatment for renal cell carcinoma.
Zhai, Li-Hai; Guo, Li-Hong; Luo, Yang-Hui; Ling, Yang; Sun, Bai-Wang. Effective Laboratory-Scale Preparation of Axitinib by Two CuI-Catalyzed Coupling Reactions. Organic Process Research & Development. Volume 19. Issue 7. Pages 849-857. Journal; Online Computer File. (2015).
Tang, Meng; Kong, Yuanfang; Chu, Bingjie; Feng, Dan. Copper(I) Oxide-Mediated Cyclization of o-Haloaryl N-Tosylhydrazones: Efficient Synthesis of Indazoles. Advanced Synthesis & Catalysis. Volume 358. Issue 6. Pages 926-939. Journal; Online Computer File. (2016).
Hao, Gui-yun; Huang, Wei; Cen, Jun-da. Synthesis of axitinib. Zhongguo Yaowu Huaxue Zazhi. Volume 24. Issue 4. Pages 298-302. Journal. (2014).
Wang, Zhaoju. Preparation method of anti-renal cancer drug Axitinib. CN 107954982. (2018).
